Cargando…
Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer
Epithelial-to-mesenchymal transition (EMT) has been shown to be associated with tumor progression and metastasis. During this process in breast cancer, a crucial role is played by alternative splicing systems. To identify a new early prognostic marker of metastasis, we evaluated EMT-related gene exp...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356812/ https://www.ncbi.nlm.nih.gov/pubmed/27911856 http://dx.doi.org/10.18632/oncotarget.13682 |
_version_ | 1782515922196496384 |
---|---|
author | Fici, Pietro Gallerani, Giulia Morel, Anne-Pierre Mercatali, Laura Ibrahim, Toni Scarpi, Emanuela Amadori, Dino Puisieux, Alain Rigaud, Michel Fabbri, Francesco |
author_facet | Fici, Pietro Gallerani, Giulia Morel, Anne-Pierre Mercatali, Laura Ibrahim, Toni Scarpi, Emanuela Amadori, Dino Puisieux, Alain Rigaud, Michel Fabbri, Francesco |
author_sort | Fici, Pietro |
collection | PubMed |
description | Epithelial-to-mesenchymal transition (EMT) has been shown to be associated with tumor progression and metastasis. During this process in breast cancer, a crucial role is played by alternative splicing systems. To identify a new early prognostic marker of metastasis, we evaluated EMT-related gene expression in breast cell lines, and in primary tumor tissue from 31 patients with early breast cancer, focusing our attention on EMT-related splicing factors ESRP1, ESRP2 and RBFOX2. Results showed that the expression patterns of these genes were indicative of the onset of EMT in in-vitro models, but not in tissue samples. However, the ratio between ESRP1 or ESRP2 and RBFOX2 significantly decreased during EMT and positively correlated with the EMT-specific phenotype in cell models, representing a promising prognostic markers. Low ESRP1/RBFOX2 ratio value was associated with a higher risk of metastasis (p < 0.005) in early breast cancer patients, regardless other clinical features. A cut-off of ratio of 1.067 was determined by ROC curve analysis (AUC 0.8375; 95% CI 0.6963–0.9787). Our study show evidence that a decrease in this ratio correlates with cancer progression. The results provide a rationale for using ESRP1/RBFOX2 ratio as a new prognostic biomarker for the early prediction of metastatic potential in breast cancer. |
format | Online Article Text |
id | pubmed-5356812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53568122017-04-20 Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer Fici, Pietro Gallerani, Giulia Morel, Anne-Pierre Mercatali, Laura Ibrahim, Toni Scarpi, Emanuela Amadori, Dino Puisieux, Alain Rigaud, Michel Fabbri, Francesco Oncotarget Research Paper Epithelial-to-mesenchymal transition (EMT) has been shown to be associated with tumor progression and metastasis. During this process in breast cancer, a crucial role is played by alternative splicing systems. To identify a new early prognostic marker of metastasis, we evaluated EMT-related gene expression in breast cell lines, and in primary tumor tissue from 31 patients with early breast cancer, focusing our attention on EMT-related splicing factors ESRP1, ESRP2 and RBFOX2. Results showed that the expression patterns of these genes were indicative of the onset of EMT in in-vitro models, but not in tissue samples. However, the ratio between ESRP1 or ESRP2 and RBFOX2 significantly decreased during EMT and positively correlated with the EMT-specific phenotype in cell models, representing a promising prognostic markers. Low ESRP1/RBFOX2 ratio value was associated with a higher risk of metastasis (p < 0.005) in early breast cancer patients, regardless other clinical features. A cut-off of ratio of 1.067 was determined by ROC curve analysis (AUC 0.8375; 95% CI 0.6963–0.9787). Our study show evidence that a decrease in this ratio correlates with cancer progression. The results provide a rationale for using ESRP1/RBFOX2 ratio as a new prognostic biomarker for the early prediction of metastatic potential in breast cancer. Impact Journals LLC 2016-11-29 /pmc/articles/PMC5356812/ /pubmed/27911856 http://dx.doi.org/10.18632/oncotarget.13682 Text en Copyright: © 2017 Fici et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Fici, Pietro Gallerani, Giulia Morel, Anne-Pierre Mercatali, Laura Ibrahim, Toni Scarpi, Emanuela Amadori, Dino Puisieux, Alain Rigaud, Michel Fabbri, Francesco Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer |
title | Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer |
title_full | Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer |
title_fullStr | Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer |
title_full_unstemmed | Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer |
title_short | Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer |
title_sort | splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356812/ https://www.ncbi.nlm.nih.gov/pubmed/27911856 http://dx.doi.org/10.18632/oncotarget.13682 |
work_keys_str_mv | AT ficipietro splicingfactorratioasanindexofepithelialmesenchymaltransitionandtumoraggressivenessinbreastcancer AT galleranigiulia splicingfactorratioasanindexofepithelialmesenchymaltransitionandtumoraggressivenessinbreastcancer AT morelannepierre splicingfactorratioasanindexofepithelialmesenchymaltransitionandtumoraggressivenessinbreastcancer AT mercatalilaura splicingfactorratioasanindexofepithelialmesenchymaltransitionandtumoraggressivenessinbreastcancer AT ibrahimtoni splicingfactorratioasanindexofepithelialmesenchymaltransitionandtumoraggressivenessinbreastcancer AT scarpiemanuela splicingfactorratioasanindexofepithelialmesenchymaltransitionandtumoraggressivenessinbreastcancer AT amadoridino splicingfactorratioasanindexofepithelialmesenchymaltransitionandtumoraggressivenessinbreastcancer AT puisieuxalain splicingfactorratioasanindexofepithelialmesenchymaltransitionandtumoraggressivenessinbreastcancer AT rigaudmichel splicingfactorratioasanindexofepithelialmesenchymaltransitionandtumoraggressivenessinbreastcancer AT fabbrifrancesco splicingfactorratioasanindexofepithelialmesenchymaltransitionandtumoraggressivenessinbreastcancer |